Iron Status and Hypoxic Pulmonary Vascular Responses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase. We have previously shown that raising iron by giving an infusion of iron into a vein reduces this pressure rise and that lowering iron by giving a drug that binds iron, magnifies this response. This is potentially a clinically important observation since iron-deficient people may be at increased risk of pulmonary hypertension if exposed transiently or permanently to hypoxia due to lung disease or residence at high altitude; furthermore if this were true then intravenous iron could be an important treatment in this patient group in the event of hypoxic exposure. The observed effects of iron on PASP are likely to be because iron levels affect oxygen sensing. Low iron levels make the body behave as if exposed to low oxygen by inhibiting the breakdown of the family of oxygen-sensing transcription factors, 'hypoxia inducible factor' or HIF. This includes one of the body's normal responses to low oxygen levels - raising blood pressure through the lungs.

This study will answer the question (1) do iron-deficient volunteers have a greater rise in PASP with hypoxia than those who are iron-replete, and (2) does giving intravenous iron cause a greater reduction in the rise in PASP in those who are iron-deficient than iron-replete? The purpose of this study is not to test the safety or clinical efficacy of iron which is already known.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iron Deficiency In Pulmonary Hypertension

NCT01288651

Idiopathic Pulmonary Arterial Hypertension

UNKNOWN PHASE4

Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension

NCT01847716

Muscle Weakness Pulmonary Arterial Hypertension

TERMINATED

Oxygen Treatment and Pulmonary Arterial Hypertension

NCT03683082

Pulmonary Arterial Hypertension

UNKNOWN NA

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

NCT01673555

Anaemia

COMPLETED PHASE1

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

NCT04231084

Pulmonary Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Hypoxia Pulmonary Arterial Hypertension Iron Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iron-deficient

Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Group Type OTHER

Intravenous administration of ferric carboxymaltose

Intervention Type DRUG

Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Subacute hypoxic exposures

Intervention Type OTHER

Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion

Iron-replete

Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Group Type OTHER

Intravenous administration of ferric carboxymaltose

Intervention Type DRUG

Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Subacute hypoxic exposures

Intervention Type OTHER

Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous administration of ferric carboxymaltose

Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Intervention Type DRUG

Subacute hypoxic exposures

Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ferinject Hypoxia Hypoxic challenge

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to give informed consent for participation in the study
* Men and women aged 18 years or older and generally in good health
* Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure
* For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation \<16%
* For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%

Exclusion Criteria

* Haemoglobin \<8.0g/dl
* Haemoglobinopathy
* Iron overload defined as ferritin \>300microg/L
* Hypoxia at rest or on walking (SaO2 \<94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease
* Exposure to high altitude (\>2,500m) within the previous six weeks or air travel \>4 hours within the previous week
* Iron supplementation or blood transfusion within the previous 6 weeks
* Pregnancy or breast feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes